Company Overview and News

 
Vilas Fund, LP Q1 '18 Letter To Partners - #28 Since Inception, Long Pharma

2018-04-20 seekingalpha
The performance of the Vilas Fund, LP, the S&P 500 and applicable HFR Index, as of March 31, 2018, follows:
Upvote Downvote

 
Can S.E.T. Aid Zimmer (ZBH) Q1 Earnings Despite Supply Woes?

2018-04-16 zacks
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) is set to report first-quarter 2018 results on Apr 26, before the markets open.
Upvote Downvote

 
ZBH / Zimmer Biomet Holdings, Inc 8-K (Current Report)

2018-04-13 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
Supply Delay Hits Zimmer Biomet, Operational Plan Buoys Hope

2018-04-09 zacks
On Apr 6, we issued an updated research report on Zimmer Biomet Holdings Inc. (ZBH - Free Report) . Issues like macroeconomic uncertainties, pricing pressure and unfavorable currency fluctuations adversely impacted Zimmer Biomet’s sales over the recent past. The company carries a Zacks Rank #4 (Sell).
Upvote Downvote

2
ZBH / Zimmer Biomet Holdings, Inc 8-K (Current Report)

2018-04-06 sec.gov
zbh-8k_20180402.htm UNITED STATES
Upvote Downvote

 
ZBH / Zimmer Biomet Holdings, Inc DEF 14A

2018-04-02 sec.gov
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
ZBH / Zimmer Biomet Holdings, Inc DEFA14A

2018-04-02 sec.gov
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

 
3D Printing in Vogue: 4 MedTech Stocks to Keep an Eye On

2018-03-29 zacks
Technological progress has been a constant for decades, making lives easier. Currently, the global mantra to success is adapting and upgrading to trending technologies.
Upvote Downvote

 
Trade War Fears Grip MedTech: 3 Stocks on the Line of Fire

2018-03-28 zacks
The trade war cacophony has spread far and wide, not sparing the investment world. The conflict between two of the world’s biggest economies has led Dow to fall more than 1,100 point in just two days last week. Although it is gradually recovering, the market is still fraught with possibilities of other outbreaks. The 10 sectors that have been identified by Trump for imposition of higher tariff are now on investors’ radar.
Upvote Downvote

 
A Look at Medtronic’s Technical Indicators

2018-03-27 editors.aws.marketrealist
On March 26, 2018, Medtronic (MDT) stock was trading ~3.4% below its 200-day moving average and ~2.8% below its 50-day moving average. The stock registered its 52-week low trading activity on March 23, 2018. This trend was partly triggered by concerns of a trade war between the US and China. However, these fears were allayed to a certain extent by reports of negotiations between the two countries on March 26, 2018.
Upvote Downvote

 
Trade War Fears Triggered Medtronic’s Stock Decline on March 23

2018-03-27 editors.aws.marketrealist
Medtronic (MDT) stock traded at its 52-week low of $76.41 on March 23, 2018. The US and most of the global markets registered weakness due to heightened concerns of a trade war between the United States and China. Medtronic stock fell ~2.3% during morning trading and declined ~2.1% during the day.
Upvote Downvote

 
ZBH / Zimmer Biomet Holdings, Inc 8-K (Current Report)

2018-03-19 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
Orthopedic Device Market Gains Momentum: 3 Stocks in Focus

2018-03-19 zacks
“At some point in every person's life, you will need an assisted medical device … as you age and you have a hip replacement or a knee replacement or a pacemaker.”
Upvote Downvote

 
Reading Dentsply Sirona’s Recent Stock Performance

2018-03-15 editors.aws.marketrealist
On March 13, 2018, Dentsply Sirona (XRAY) closed trading at a price of $57.80 per share. The company registered its 52-week high of $68.98 on November 28, 2017, while a 52-week low of $52.54 was reported on August 21, 2017.
Upvote Downvote

 
Why Is Wall Street Still Upbeat on Dentsply Sirona’s Growth Potential in 2018?

2018-03-15 editors.aws.marketrealist
Dentsply Sirona (XRAY) is one of the leading dental technology, equipment, and consumables providers in the United States. But the company has been going through some tough times following the merger of Sirona Dental Systems and Dentsply International and the subsequent formation of Dentsply Sirona in February 2016.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 98956P102